triamcinolone hexacetonide
Commercial- Indications
- Not specified
Company intelligence / Profile preview
RIEMSER
Greifswald, Germanyriemser.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Commercial
01
Overview
RIEMSER was a specialty pharmaceutical company focused on commercializing and managing the life cycle of niche pharmaceuticals with high unmet medical needs. Its marketed portfolio included drugs for oncology, anti-infectives, dermatology, neurology, and cardiovascular diseases. The company expanded through acquisition—most notably Keocyt—and was acquired by ESTEVE Pharmaceuticals in the early-mid-2020s.
- Therapeutic areas
- OncologyDermatologyCardiovascularNeurologyInfectious Diseases
- Modalities
- EnzymeSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
ADIENNE Pharma & Biotech
Beyond the preview
Go deeper on RIEMSER.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIEMSER.